Apogee Therapeutics (NASDAQ:APGE) Given "Outperform" Rating at Wedbush

Key Points

• Apogee Therapeutics' stock rating was reaffirmed as "outperform" by Wedbush, with a price target of $90.00, suggesting a potential upside of 159.74%.
• Several analysts, including BTIG Research and Guggenheim, have given Apogee a "buy" rating, with price targets ranging from $100.00 to $116.00.
• Insider Carl Dambkowski sold 2,725 shares at an average price of $37.78, while institutional ownership stands at approximately 79.04%.

Wedbush reiterated their outperform rating on shares of Apogee Therapeutics (NASDAQ:APGE - Free Report) in a research note released on Monday morning,RTT News reports. Wedbush currently has a $90.00 price objective on the stock. Wedbush also issued estimates for Apogee Therapeutics' Q3 2025 earnings at ($1.21) EPS, Q4 2025 earnings at ($1.24) EPS, FY2025 earnings at ($4.53) EPS, Q1 2026 earnings at ($1.27) EPS, Q2 2026 earnings at ($1.18) EPS, Q3 2026 earnings at ($1.18) EPS, Q4 2026 earnings at ($1.13) EPS, FY2026 earnings at ($4.75) EPS, FY2027 earnings at ($4.75) EPS, FY2028 earnings at ($6.13) EPS and FY2029 earnings at ($5.99) EPS.

A number of other research analysts have also recently weighed in on the stock. Citigroup restated a "buy" rating on shares of Apogee Therapeutics in a report on Monday, July 7th. Guggenheim restated a "buy" rating and issued a $116.00 price objective on shares of Apogee Therapeutics in a report on Wednesday, July 2nd. Finally, BTIG Research lifted their price objective on shares of Apogee Therapeutics from $100.00 to $115.00 and gave the company a "buy" rating in a report on Monday, July 7th. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has an average rating of "Buy" and a consensus price target of $99.00.

Apogee Therapeutics Stock Down 0.4%

Shares of APGE traded down $0.14 during trading on Monday, reaching $37.98. 47,146 shares of the company traded hands, compared to its average volume of 745,846. The stock has a market cap of $1.75 billion, a PE ratio of -9.19 and a beta of 1.43. The stock has a 50-day simple moving average of $40.16 and a 200-day simple moving average of $37.95. Apogee Therapeutics has a twelve month low of $26.20 and a twelve month high of $63.50.

Apogee Therapeutics (NASDAQ:APGE - Get Free Report) last announced its quarterly earnings data on Monday, August 11th. The company reported ($1.13) earnings per share for the quarter, missing analysts' consensus estimates of ($1.03) by ($0.10). On average, equities research analysts predict that Apogee Therapeutics will post -3.09 EPS for the current year.

Insider Transactions at Apogee Therapeutics

In related news, insider Carl Dambkowski sold 10,090 shares of Apogee Therapeutics stock in a transaction that occurred on Wednesday, July 2nd. The shares were sold at an average price of $45.09, for a total value of $454,958.10. Following the completion of the transaction, the insider owned 238,998 shares in the company, valued at $10,776,419.82. The trade was a 4.05% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders have sold a total of 15,540 shares of company stock valued at $658,625 in the last ninety days. 42.77% of the stock is owned by insiders.

Institutional Trading of Apogee Therapeutics

Several institutional investors have recently modified their holdings of the stock. Ameriprise Financial Inc. purchased a new stake in shares of Apogee Therapeutics during the 4th quarter worth approximately $259,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of Apogee Therapeutics by 4.1% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 23,835 shares of the company's stock worth $1,078,000 after buying an additional 931 shares during the last quarter. Rhumbline Advisers lifted its position in shares of Apogee Therapeutics by 3.2% during the 1st quarter. Rhumbline Advisers now owns 54,385 shares of the company's stock worth $2,032,000 after buying an additional 1,665 shares during the last quarter. BNP Paribas Financial Markets purchased a new stake in shares of Apogee Therapeutics during the 4th quarter worth approximately $219,000. Finally, Bank of New York Mellon Corp lifted its position in shares of Apogee Therapeutics by 93.3% during the 1st quarter. Bank of New York Mellon Corp now owns 214,231 shares of the company's stock worth $8,004,000 after buying an additional 103,404 shares during the last quarter. Hedge funds and other institutional investors own 79.04% of the company's stock.

Apogee Therapeutics Company Profile

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.